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ABSTRACT
Objective: Our aims were to estimate 1) the costs of
hospital treatment and 2) the value of lost production due
to early death associated with overweight and obese
patients, and then to extrapolate the ﬁndings to national
costs.
Methods: We use regression models to analyze survival,
expected number of days in hospital treatment for
patients with different body mass index (BMI), and costs
with data obtained from screening of 33,196 middle-aged
subjects living in Malmö, Sweden, and collected during a
15-year follow-up period. We subsequently scale up costs
to national aggregate level using the BMI prevalence data
from the screening project to the national population.
Results: The total excess hospital (somatic, psychiatric)
care cost (Swedish krona or SEK) for the national health-
care budget, excess as compared to normal weight
patients for obese (BMI > 30) and overweight
(25 £ BMI < 30) was estimated to SEK2155 million per
annum (US$269 million, assuming US$1 = SEK8), or
about 2.3% of total hospital care costs in Sweden. The
corresponding indirect costs due to early death were esti-
mated to SEK2935 million (US$367 million). For males at
age 55, the potential hospital costs saving, excluding costs
of the intervention that could be gained by an interven-
tion that successfully and safely could alter the weight of
an obese individual to become normal weight, was esti-
mated on average to SEK4434 (US$554) per annum.
Conclusion: Hospital treatment costs are found to be
higher for obese and overweight patients than for normal
weight patients indicating potential cost savings especially
on indirect costs by effective, safe and low cost weight-
loss intervention.
Keywords: BMI, costs, hospital bed-days, obesity,
survival.
Introduction
Obesity is a well-known risk factor for increased
morbidity and premature mortality [1–4]. The
World Health Organization (WHO) uses the body
mass index (BMI) as a criterion for deﬁning obesity.
This index is calculated as the ratio between a per-
son’s weight in kilogram and the person’s length in
meter squared (kg/m2). When this ratio is greater
than 30 a person is deﬁned to be obese and when
the ratio takes a value between 25 and 30 kg, a per-
son is deﬁned to be overweight. Normal weight is
deﬁned for persons with BMI 18.5–25 and subjects
with BMI < 18.5 as underweight [5]. In this study
we will analyze hospitalization for subjects with
BMI > 18.5 only.
Numerous observational studies from many pop-
ulations, both in men and women, have found obes-
ity to be associated with cardiovascular diseases,
type 2 diabetes, and some forms of cancer, e.g.,
breast cancer and endometrial cancer of corpus
uteri [6–9]. As a consequence of the association
between obesity and increased morbidity, longer
hospital stays, and greater risk for complications
following medical intervention, obesity is also asso-
ciated with increased costs of treatment [10–16].
In the literature there are a few studies that have
reported on the association between BMI and
health-care costs [17–19]. All these studies provide
estimates of the cost of illness (COI) attributed to
obesity at one point in time using the prevalence
approach. The estimates are based on calculations
of the total annual expenditure of a particular dis-
ease, e.g., type 2 diabetes multiplied by an obesity-
etiological fraction that measures the impact of
obesity as a risk factor for type 2 diabetes. Never-
theless, COI estimates based on the prevalence
approach are not very useful for guiding decisions
on prevention because the time dimension of the ill-
ness development is not considered. To provide
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information for decisions on prevention, the eco-
nomic analysis needs to account for the time
between the investments in preventing efforts and
the beneﬁts in reduced treatment costs, i.e., the time
dimension. Cohort studies using the incidence
approach can provide such observational informa-
tion [20].
In this study we will seek to provide further evi-
dence of the association between obesity and treat-
ment costs. In particular we seek to address two
speciﬁc questions: 1) are the hospital treatment
costs for obese and overweight patients higher than
for normal-weight patients, and if so, how much
does this higher cost imply for the national
Swedish health-care budget; and 2) are there any
differences in life expectancy between obese and
overweight patients from normal weight patients,
and if so, how much is the associated costs for lost
production?
Subjects and Methods
Subjects
To answer the two questions posed, we used hospi-
tal data from medical records for middle-aged sub-
jects of both sexes, recruited from the Malmö
Prevention Project (MPP). All subjects in MPP were
originally recruited from Malmö city, Sweden.
Between 1974 and 1984, a total of 22,444 men
born between 1921 and 1949 (age range 35–
51 years) and 10,533 corresponding women, con-
stituting 70–75% of the total population in these
birth cohorts (85% born in Sweden, 99% white),
took part in the MPP. The project was carried out at
the Department of Medicine, Malmö University
Hospital, in southern Sweden. The aim of MPP was
to screen the local population for cardiovascular
risk factors and alcohol overconsumption. The sub-
jects had a mean follow-up of 17 years (range 0–
24 years). We have limited this study to the ﬁrst
15 years of follow-up, because the proportion of
patients lost to follow-up gradually accelerates
beyond 15 years. A total of 23,365 subjects (70%)
had a follow-up period of at least 15 years. Follow-
up data were derived from register linkage analyses,
covering a time period with expansion of the health-
care sector and medical treatment modalities. Nev-
ertheless, due to ﬁnancial restrictions in health care
in general, the mean number of days of each episode
of hospitalization has gradually decreased for most
common diagnostic categories. The loss of subjects
to follow-up is related at least partly to mortality in
about one-third of these subjects, as well as loss of
a number of subjects that had emigrated abroad
during follow-up.
Data on screening routines have previously been
published as well as some follow-up analyses [21–
24]. In Malmö city, there is only one central univer-
sity hospital for the local population (250,000
inhabitants). The patients were classiﬁed into BMI
Groups using the WHO criterion. Throughout this
paper, BMI refers to baseline BMI. Baseline charac-
teristics of the subjects are presented in Table 1.
Although the study was designed as a screening
project for cardiovascular events, we believe the
BMI data generated from the study can also be
used to answer the two questions that we have
posed for this study. This is especially so because of
the Swedish system of using a 10-digit personal
number for all citizens, making it possible to trace
persons even if they move around and to receive
in-hospital care in different cities. Not many coun-
tries have the same administrative system and
therefore we believe a study on the long-term eco-
nomic consequences of obesity is suitable to do in
Sweden.
Table 1 Baseline characteristics of subjects (N)
Normal weight Overweight Obese 
Male Female Male Female Male Female
N 12,823 6,662 7,931 2,844 1,382 1,068
Age group
N < 45 52.7% 28.3% 42.9% 12.1% 38.5% 10.1%
N 45–54 43.1% 40.0% 50.5% 44.4% 54.7% 40.2%
N ≥ 55 4.2% 31.7% 6.6% 43.5% 6.8% 49.7%
100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Age range
Min 25.5 28.2 27.9 28.2 28.1 28.5
Max 61.2 57.6 61.1 57.4 60.8 57.0
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age 43.0 (6.6) 48.6 (7.9) 44.7 (5.4) 51.7 (5.5) 45.3 (6.1) 52.2 (5.4)
BMI 22.6 (1.6) 22.1 (1.7) 26.9 (1.3) 27.0 (1.4) 32.4 (2.4) 33.4 (3.4)
Follow-up years 18.6 (3.6) 14.5 (4.5) 18.6 (3.7) 13.2 (4.0) 17.9 (4.5) 12.8 (4.0)
BMI, body mass index.
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To answer the questions that we have posed for
this study we will estimate the following equation:
HAggregated  =  f(age, sex, BMI group) (1)
where HAggregated = number of days in hospital over
the follow-up time, which depends on age, sex and
baseline BMI group, i.e., normal weight, over-
weight, and obese.
The cost of hospital treatment we subsequently
estimate by multiplying HAggregated with an average
cost per day of care in hospital. We use administra-
tive prices for the costs of 24 hour hospital stay at
the general medical ward and the psychiatric ward
from Malmö City University Hospital. These prices
were for the year 2003 SEK3899 at the medical
ward and SEK3055 at the psychiatric ward. We use
a weighted average cost of inpatient stay with
weight two-thirds for the general medical ward and
one-third for the psychiatric ward. These weights
reﬂect roughly the pattern of admission of the
screened population.
Method and statistical analysis. The observed data
on hospitalization had a much skewed distribu-
tion. There was a tendency toward a pattern of
either no hospitalization at all in a given year, or
frequent and, in some cases, lengthy hospitaliza-
tion. Therefore we tried to discriminate between
two subgroups without hospitalization and with
hospitalization within a given year, and analyze the
hospitalization rate in the latter one.
To obtain numerical estimate of Equation 1 we
use three regression equations, one for the survival
time (T) (Equation 2), one for the probability (Pr) of
hospitalization in a given year (Equation 3), and
one for the number of days in hospital (H) given
hospitalization (Equation 4), deﬁned as follows:
ln (T(D1, D2, D3, Age)) = a1 + a2*D1 + 
a3*D2 + a4*D3 + a5*Age + e1 (2)
Pr {H(D1, D2, D3, Age) > 0} = (1 + exp(b1 + 
b2*D1 + b3*D2 + b4*D3 + b5*Age + e2))-1 (3)
y(D1, D2, D3, Age) = ln (H(D1, D2, D3, 
Age)) = (g 1 + g2*D1 + g3*D2 + g4*D3 + 
g4*Age + e3) (4)
For Equation 2 we use an accelerated failure time
model where age, two dummy variables for BMI
group (D1 and D2), and one dummy variable for
gender (D3) are explanatory variables, and the sur-
vival times (T) are assumed to have a Weibull dis-
tribution. This method assumes a parametric shape
of the survival function, whereas nonparametric
methods such as the Kaplan–Meier estimator make
no such assumptions. Our approach enables the use
of age as a continuous explanatory variable. The ﬁt-
ted parametric survival function is then used to
compute the probability of survival beyond t years
of follow-up time, Pr {T(D1, D2, D3, Age) > t}. In
Equation 3 we do a logistic regression of the prob-
ability of nonzero number of days in hospital in a
given year. Finally in Equation 4, we do a linear
regression of the log number of days in hospital
conditional on nonzero number of days. All these
regression equations have age, BMI group, and gen-
der as explanatory variables. The dummy variables
D1, D2, and D3 is set equal to 1 for overweight,
obese, and male patients, respectively, otherwise 0,
and we divided the data into individual patient-
years, so that each subject provided up to 15 years
of observation. The log-transform in Equation 4
necessitates the use of a smearing estimator to avoid
bias when using the model to predict onto the nat-
ural scale [25].
Having obtained numerical estimates of
Equations 2–4 numerical estimate of Equation 1 is
derived as follows:
HAggregated(D1, D2, D3, Age) = {Pr{ T(D1, D2, D3, 
Age) > t} * Pr {H(D1, D2, D3, Age + t - 1) > 0] * 
exp(y(D1, D2, D3, Age + t - 1) + s)}
where s is a smearing estimate for loglinear models,
which is used to adjust for transformation bias, and
age in Equations 3 and 4 is substituted with
age + t - 1 to account for follow-up time.
We deﬁne indirect costs equal to the value of pro-
duction that is lost due to death before retirement
age. We deﬁne this value equal to the number of
years between age at death and age 65 times the
annual wage including the social costs of labor
(social insurance, pension, etc.) of the deceased. We
follow standard convention and assume that the
wage reﬂect the value of production. We have
assumed that all subjects in all BMI groups have an
average wage equal to the national average by age
and gender [26].
Both health-care costs and indirect costs due to
loss of production were estimated for a period of
15 years, in male and female subjects of ages 30–60,
in each BMI group. We sum up the discounted costs
over 15 years using a discount rate of 3%. The dif-
ferences as compared to normal weights were esti-
mated on a yearly basis.
We make a ﬁnal aggregation of these costs by
projecting the cost estimates onto the Swedish pop-
ulation. Each stratum in the population, deﬁned by
age (30–60), BMI group, and gender, were multi-
t=
Â
1
15
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plied by the predicted excess cost weighted by rela-
tive prevalence within the study subjects. In this
context, the normal weight subjects yield zero costs
in analogy with the methods described above. The
resulting estimate is therefore the estimated cost due
to obesity and overweight as compared to the hypo-
thetical situation where all are normal weight.
The R language was used for statistical analyses
and graphics [27].
Results
Survival Pattern
Our parameter estimates of Equation 2 are reported
in Table 2.
Our model for survival showed that male sub-
jects have a higher risk of death than female subjects
(P < 0.0001), and that the risk is higher in obese
(P < 0.0001) as compared to normal weight sub-
jects. No difference was detected between over-
weight and normal weight subjects. In addition, the
model conﬁrms the expected result that the risk of
death increases with age (P < 0.0001). Predicted
survival curves for 60-year-old male in each BMI
group are shown in Figure 1.
Hospitalization Rate
Parameter estimates of Equations 3 and 4 are
reported in Tables 3 and 4.
The logistic model, Equation 3, shows the risk on
nonzero hospitalization to increase with age (OR
1.031; 95% CI 1.029–1.032 for one year older), for
male as compared to female subjects (OR 1.18; CI
1.15–1.21), for obese (OR 1.52; CI 1.47–1.58) and
overweight (OR 1.14; CI 1.11–1.16) as compared
to normal weight. The predicted probabilities of
hospitalization are shown in Figure 2, for 50-year-
old male subjects in each BMI group.
Table 4 reports the parameter estimates for
Equation 4. The number of days in hospital
increases by age (P < 0.0001), but no statistical
Table 2 Parameter estimates for survival time, Equation 2 estimated with N = 32,710 patients
Value Std. error z value P value Pr{ > |z|}
a1 (Intercept) 7.2398 0.10714 67.57 <0.0001
aAge -0.0571 0.00175 -32.69 <0.0001
aBMI = Normal 0
aBMI = Obese -0.2472 0.03306 -7.48 <0.0001
aBMI = Overweight -0.0154 0.02112 -0.73 0.4610
aSex = Female 0
aSex = Male -0.5039 0.02990 -16.85 <0.0001
Log (scale) -0.5286 0.01573 -33.61 <0.0001
Loglik (model) -20828.5
Chisq. 1567.07
Likelihood test ratio versus intercept Chisq. (c2) = 1567, P value < 0.0001.
Figure 1 Estimated survival in male subjects, aged 60.
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Figure 2  Estimated probability of hospitalization in male subjects,
aged 60.
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signiﬁcant difference in hospitalization by gender.
The rate was signiﬁcantly higher for obese
(P = 0.0024) and signiﬁcantly lower for overweight
subjects (P = 0.0026), as compared to normal sub-
jects. Unfortunately, the predictive power of the
equation is rather modest, adjusted R2 about 0.9%.
In this study, however, we are not seeking to pre-
dict the individual variation in number of days in
hospital, but rather the difference between groups
of individuals. Our model clearly shows that there
are differences in the number of days in hospital
between groups of individuals with different BMI
values, hence, we will use this model to answer the
questions that we have posed for this study. Figure 3
shows predicted number of days in hospital using
Equation 4 in 60-year-old male subjects in each
BMI group.
Expected Incremental Costs of Hospitalization and 
Indirect Cost Due to Loss of Production over 15 years
Using the results from Equations 2–4 we can now
estimate Equation 1. The result is presented in
Table 5. In this table we report the expected num-
bers of days in hospital for age cohorts 30–60, accu-
mulated over 15 years along with the incremental
cost of hospitalization as compared to normal
weight subjects. A graphical presentation of the
expected number of days in hospital for male sub-
jects of different BMI groups is given in Figure 4.
The curves in Figure 4 are generated as the product
of the predicted probability of survival, the pre-
dicted probability of hospitalization, and the pre-
dicted number of days in hospital. Note that the
curve for overweight lies above the curves for nor-
mal weight, whereas in Figure 3 the curve for over-
weight lies below the curves for normal weight. The
reason why the curve for overweight shifts its posi-
tion in Figure 4 is that overweight patients have a
higher probability of hospitalization.
The mean number of days in hospital of normal
weight patients and overweight patients are, how-
ever, very similar, while obese patients have more
days than normal weight. In Table 5 one may also
note that the number of days in hospital increases
by age in all BMI groups.
Estimates of the indirect costs due to loss of pro-
duction are reported in Table 6. Overweight and
normal weight are very similar, while obese has
greater loss. The indirect cost of lost production
Table 3 Parameter estimates probability of having nonzero hospitalization rate, Equation 3 estimated with N = 32,710
patients (459,511 patient-years)
Estimate Std. error z value
P value 
Pr{ > |z|} OR*
b1 (Intercept) -4.112957 0.03995 -103.36 <0.0001
bAge 0.0306225 0.0006842 44.76 <0.0001 1.031
bBMI = Normal 0
bBMI = Obese 0.4182596 0.0181195 23.08 <0.0001 1.52
bBMI = Overweight 0.1276276 0.0112628 11.33 <0.0001 1.14
bSex = Female 0
bSex = Male 0.1668386 0.0119167 14.00 <0.0001 1.18
*OR (odds ratio) = expb.
Likelihood test ratio versus intercept Chisq. (c2) = 2852, P value < 0.0001.
Table 4 Parameter estimates for the log of number of days
in hospital, Equation 4 estimated with N = 18,153 patients
(41,228 patient-years)
Estimate Std. error t value
P value
Pr{ > |t|}
g1 (Intercept) 0.9222788 0.0456287 20.213 <0.0001
gAge 0.0147012 0.0007916 18.571 <0.0001
gBMI = Normal 0
gBMI = Obese 0.0659055 0.0216860 3.039 0.0024
gBMI = Overweight -0.0412887 0.0137294 -3.007 0.0026
gSex = Female 0
gSex = Male 0.0104361 0.0141413 0.738 0.46053
Adjust. R2 0.0091 Figure 3 Predicted number of days in hospital in male subjects, aged
60.
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increases by age up to age 50 because average
annual salary (earnings) increases by age. After age
50 indirect cost declines because the number of
years to retirement age, 65, becomes less than
15 years.
Projecting the Costs onto the Swedish Population
Sweden has a population of some 3.7 million
persons in the ages 30–60, and we use the cost
estimates presented above to project onto this
population and report the results in Table 7. The
average annual hospital costs accumulated over
15 years is estimated to 2.1 billion SEK and practi-
cally all costs (97%) can be attributed to obese
patients. Table 7 also reveals a marked gender dif-
ferences in costs. The average annual hospital costs
for male patients are estimated to 1.36 billion (63%
of total) and 0.81 billion (37% of total) for female
patients. In Table 7 we also report our estimate of
indirect costs due to death before retirement age.
Total indirect costs are higher than total hospital
costs. The average annual indirect cost is estimated
to 2.9 billion, which is 38% higher than our esti-
mate of the annual costs of hospital treatment for
obese and overweight patients.
Discussion
In this study we have sought to provide answers to
two questions. First we raised the question if hos-
pital treatment costs for obese and overweight are
higher than for normal weight subjects. To this
question we can say yes. In our statistical analysis,
we found the mean expected number of days in
hospitals to be signiﬁcantly higher for obese and
overweight patients than for normal weight
patients, cf., Table 5. This difference in number of
days of care in hospital we have calculated in
Table 7 translates into an aggregate cost for the
Swedish health-care budget of some 2.1 billion SEK
per annum. This ﬁgure we may now compare to
another recently produced study on the problems
and costs of obesity in Sweden. The Swedish Coun-
Table 5 Mean (expected) days in hospital in normal weight, overweight, and obese subjects, and excess days and costs of
excess days in hospital for overweight and obese subjects as compared to normal weight (mean and 95% conﬁdence intervals),
by gender and selected age, over 15 years
Age*
Expected days in hospital
Mean days per patient
Excess days in hospital
Mean days per patient (95% CI)†
Cost‡ of excess days in hospital
 Mean cost per patient (95% CI) 
Normal Overweight Obese  Overweight Obese  Overweight Obese
Male
30 10.0 10.9 15.8 0.82 (0.27–1.35) 5.72 (4.10–7.62) 2369 (778–3904) 16,567 (11,874–22,096)
35 12.4 13.4 19.3 0.99 (0.32–1.64) 6.94 (5.00–9.21) 2883 (928–4759) 20,130 (14,507–26,731)
40 15.3 16.5 23.6 1.20 (0.37–1.98) 8.33 (6.02–11.02) 3479 (1085–5759) 24,220 (17,514–32,052)
45 18.7 20.1 28.5 1.43 (0.43–2.37) 9.84 (7.13–13.00) 4157 (1248–6907) 28,733 (20,813–37,946)
50 22.7 24.3 34.0 1.68 (0.47–2.80) 11.37 (8.23–15.02) 4897 (1394–8177) 33,378 (24,172–44,051)
55 27.1 29.0 39.8 1.93 (0.50–3.24) 12.69 (9.16–16.79) 5650 (1490–9503) 37,572 (27,142–49,653)
60 31.7 33.8 45.1 2.14 (0.48–3.65) 13.43 (9.61–17.88) 6328 (1465–10,761) 40,350 (28,960–53,576)
Female
30 8.5 9.2 13.5 0.71 (0.22–1.17) 4.94 (3.47–6.65) 2042 (643–3386) 14,295 (10,032–19,276)
35 10.6 11.4 16.6 0.86 (0.27–1.43) 6.05 (4.29–8.10) 2502 (779–4151) 17,527 (12,416–23,486)
40 13.1 14.2 20.5 1.05 (0.32–1.75) 7.37 (5.27–9.82) 3051 (936–5068) 21,371 (15,259–28,479)
45 16.2 17.4 25.1 1.27 (0.38–2.12) 8.90 (6.40–11.80) 3693 (1100–6146) 25,857 (18,570–34,296)
50 19.9 21.4 30.5 1.53 (0.44–2.55) 10.63 (7.66–14.05) 4434 (1277–7401) 30,945 (22,312–40,902)
55 24.2 26.0 36.7 1.81 (0.49–3.03) 12.47 (9.00–16.45) 5265 (1451–8825) 36,452 (26,329–48,082)
60 29.2 31.3 43.5 2.10 (0.54–3.55) 14.26 (10.28–18.82) 6149 (1588–10,367) 41,941 (30,257–55,310)
*We selected the age span 30–60 years because this age span covers the 95% CI interval of age in our sample population.
†We use Boots-trap techniques to generate our 95% CI.
‡Discounted at 3%.
Figure 4 Expected number of accumulated days in hospital by age at
beginning of period.
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cil on Technology Assessment of Health Care, 2003
(SBU) have reviewed the literature on the problem
and costs of obesity treatment and from this review
they assume that the cost of obesity is equal to 2%
of the total health-care costs in Sweden [28]. This
assumption, which is based on literature review of
costs estimates of overweightness and obesity pro-
duced in other countries, yields total costs of 3 bil-
lion SEK for the year 2002. This is higher than our
cost estimate in this study of 2.1 billion. The reason
for this is that in our study we have only estimated
the total costs of all hospital treatment and have
not included the costs of outpatient treatments
including costs of drugs. In the Swedish health-care
system, around 60% of the direct health-care costs
are for hospital care, which would imply that out of
the 3 billion estimated by SBU 1.8 billion should be
for hospital care and this is lower than our cost
estimate of 2.1 billion. One explanation for this
discrepancy between our estimate and the estimate
provided by SBU is that in our study, we use panel
date drawn from the population of Malmö city.
Malmö is Sweden’s third largest city and access and
utilization of health care (hospital care) may not be
fully representative for the country population. The
discrepancy may also of course be due to differ-
ences in methodology. Our approach is a much
more rigorous approach than the simple approach
used by SBU. Nevertheless, our approach and the
approach taken by SBU arrive at total costs
estimates that are within reasonable margin
comparability.
The second question we raised in this study was
if there were any differences in survival for subjects
with different BMI. To this question we can also say
yes. Obese subjects were found to have a signiﬁ-
cantly lower probability of survival than normal
weight subjects, cf., result Table 2. These differences
in survival we have calculated in Table 7 translate
into an aggregate indirect cost of lost production
due to early death for the Swedish society of some
2.9 billion SEK per annum. For this estimate we
have made the same assumption about the preva-
lence as reported for direct costs. This is a weak
assumption and therefore our result must be inter-
preted with great care. Nevertheless, we believe the
result gives a rough estimate of the magnitude of the
indirect costs involved for excess morbidity found
for overweight and obese patients. Our estimate,
however, is only part of total indirect costs. There
are three major reasons that give rise to indirect
costs: 1) indirect costs due to death before retire-
ment; 2) indirect costs due to early retirement on
account of morbidity; and 3) indirect costs due to
short-term absence from work on account of an ill-
ness episode. We have only estimated the indirect
costs due to death before retirement age. Unfortu-
nately, our panel data set contains no information
on early retirement on account of morbidity and the
extent of absence of work on account of short-term
illness episodes. In Sweden it is these two causes
that give rise to most of the indirect costs. Accord-
ing to a COI report published by the National
Board of Health and Social Welfare in Sweden,
Socialstyrelsen (1996), cost of early retirement and
costs of short-term absence from work accounted
for some 80% of total indirect costs in Sweden [29].
If we use this ratio on our estimated indirect cost of
2.9 billion SEK on account of death before retire-
ment, we arrive at a total indirect costs for over-
weightness and obesity of some 14.5 billion SEK
{= 2.9/(100%-80%)}.
The result in Table 5 shows the incremental costs
per patient of obese and overweight subjects as
compared to normal weight. This incremental cost
constitutes the potential costs savings that could be
gained by any therapy that could convert obese and
overweight subjects to normal weight subjects.
Against this cost saving, however, we must deduct
the cost of the therapy, which is likely to be equally
as high if not higher, so the potential for any net
hospital costs saving to be gained seems to be rather
limited. The indirect costs are substantially higher
than hospital costs so there seems to be a good
potential to make savings in indirect costs with a
therapy that could convert obese and overweight
subjects to normal weight subjects. Nevertheless, to
avoid the excess health-care cost of obesity, a pri-
mary strategy of prevention in children and young
adults based on lifestyle is the most important meas-
Table 7 Average annual projected hospital and indirect
cost (projected over 15 years), SEK mil, of overweight and
obese male and female persons in the Swedish population in
ages 30–60 as compared to the same population with normal
weight
Hospital cost (HC) Indirect costs (LP) Total
Overweight
Male 39,526 26,663 66,190
Female 40,215 9,193 49,407
Total 66,190 35,856 102,045
Obese
Male 1,320,654 2,387,908 3,708,562
Female 768,904 511,690 1,280,594
Total 2,089,558 2,899,598 4,989,156
Overweight + Obese
Male 1,360,181 2,414,571 3,774,752
Female 809,118 520,883 1,330,001
Total 2,155,747 2,935,454 5,091,202
Indirect cost measures loss of production due to early death. Costs are dis-
counted using a 3% discount rate.
Borg et al.570
ure to undertake. Besides that, new drug treatment
modalities should be developed for cost-effective
treatment of adult obesity with a favorable long-
term effectiveness and safety proﬁle.
A major limitation of our study is that we have
not been able to control for differences in diseases
among the screened population. Nor did we in this
study exclude subjects who reported that they
smoked cigarettes or had a history of cancer.
Because cancer is associated with both low and high
BMI and high medical costs, it might therefore be a
confounding factor to our estimation of costs.
Smoking is primarily associated with low BMI and
is therefore another important confounding factor
in our analysis. Excluding individuals with other
confounding factors, for example subjects with pre-
existing coronary heart disease, stroke, and type 2
diabetes, would have resulted in a reduction of the
study subpopulation characterized by metabolic
effects of obesity.
Another limitation of our study is that we have
been unable to control for differences in socioeco-
nomic status (SES) of the screened population.
Unfortunately, the data set that we have used in this
study contains insufﬁcient data to lend itself to ana-
lyze the link between SES and obesity. One study on
the link between SES and obesity concludes that the
causality can run in both directions from low SES to
obesity or from obesity to SES [30]. The conclusion
made in this study was therefore that the question
on causality was too complex to lend it self to the
conclusion that obesity was a contributing factor
for low SES. There are other common variables that
link obesity and low SES.
Most studies investigating the relationship
between health-care costs and BMI are based on the
prevalence approach and provide only a point esti-
mate of excess costs for one single year. Such studies
are, however, of limited value for assessing the value
of intervention programs. For evaluation of inter-
vention programs cohort studies, following patients
over long periods and estimating the present value
of potential cost savings, are more relevant. To our
knowledge, our study is the ﬁrst to show a statistical
signiﬁcant relationship between BMI and longitudi-
nal inpatient care costs. Other cohort studies have
established relationship between drug therapy costs
and outpatient care costs but failed in this respect
for inpatient care costs [17,19]. Nevertheless, the
previous study was based on a data set of 1286 sub-
jects, selected from 7021 adults participating in a
health survey, followed over a period of 9 years.
Our estimates were derived from a larger data set,
in which 33,332 subjects, selected from a screening
project involving 33,346 individuals, were followed
over 15 years.
In conclusion, we have found that obesity both
entails a considerable health hazard and conse-
quently gives rise to substantial hospital costs and
indirect costs due to early death. In particular we
have found that inpatient care costs are higher for
overweight and obese patients indicating potential
cost offsets especially for indirect costs by an effec-
tive and safe weight loss intervention.
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